A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ®

Bayer71 enrolled

Overview

Evaluation of the efficacy and safety of Nexavar ® in advanced Renal Cell Carcinoma (RCC) and calculation of related medical costs.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Carcinoma, Renal Cell Carcinoma, Renal Cell (Advanced)

Interventions

Sorafenib (Nexavar, BAY43-9006)DRUG

Patients with diagnosis of advanced renal cell cancer and decision taken by the investigator to prescribe Nexavar®.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with diagnosis of advanced RCC and decision taken by the investigator to prescribe Nexavar®. The patients should have sufficient knowledge of French or Dutch to be able to participate in the Study Exclusion Criteria: * Exclusion criteria must be read in conjunction with the Belgian product information

Locations (1)

Unnamed facility

Many Locations, Belgium

Outcomes

Primary Outcomes

Proportion of patients who are progression-free at one year according to the RECIST criteria. The proportion of patients who are progression-free at 1, 3, 6 and 9 months will also be calculated

Time frame: At 1, 3, 6 and 9 months and after one year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.